Boston Scientific to acquire Lumenis surgical business for $1.07B

Boston Scientific (NYSE:BSX) announced today that it entered into a definitive agreement to acquire the global surgical business of Lumenis for nearly $1.1 billion.

Marlborough, Mass.-based Boston Scientific entered into the agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of the privately-held company developing and commercializing energy-based medical solutions. The deal includes an upfront cash payment of $1.07 billion, subject to closing adjustments, according to a news release.

BPEA is slated to retain ownership of the Lumenis global aesthetics and ophthalmology businesses, while Boston Scientific picks up a surgical business expected to bring in 2021 revenues of approximately $200 million. The company expects the deal to be completed in the second half of 2021, with an immaterial impact on adjusted earnings per share this year. EPS impact is expected to be 2¢ accretive in 2022 and increasingly accret…

Read more
  • 0